French Research Tax Credit Accreditation
April 21 2010 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
21 April 2010
?
21 April 2010
Cyprotex PLC ("Cyprotex" or the Company")
Cyprotex Discovery Receives French Research Tax Credit Accreditation
Cyprotex (AIM:CRX), the drug discovery technology and information company, is
pleased to announce that it has received French research tax credit approval for
years 2009 through to 2011.
The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la
Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche",
CIR) accreditation to Cyprotex as of March 2010. This initiative allows
eligible French pharmaceutical, biotech and agricultural companies subject to
corporate tax in France, the ability to claim significant tax relief on costs
generated in R&D requirements that are outsourced to Cyprotex Discovery.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are
delighted to receive this recognition and approval from the French Ministry of
Research which will provide greater opportunities to support our current client
base and allow for improved collaborations with future French clients.'
Additional information on the French research tax credit system is available
from the Ministère de l'Enseignement Supérieur et de la Recherche site -
http://www.enseignementsup-recherche.gouv.fr/
For further information:
Cyprotex PLC
Dr. Anthony Baxter, Chief Executive Officer
Tel: +44 1625 505 100
a.baxter@cyprotex.com
www.cyprotex.com
Execution Noble & Company Limited
John Llewellyn-Lloyd
Sam Reynolds
Tel: 020 7456 9191
Public Relations
Financial Dynamics
Ben Brewerton
Ben Atwell
Mo Noonan
Tel: 020 7831 3113
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKKKDPABKDOQB
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024